PUBLICATIONS: NARRATIVE REVIEWS (PEER-REVIEWED)

2. Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother 2013;14:1585-97.
3. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012;67:255-68.
4. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol 2012;19:14-20.
5. Rafailidis PI, Polyzos A, Sgouros K, Falagas ME. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents 2011;37:283-90.
6. Peppas G, Gkegkes ID, Makris MC, Falagas ME. Biological mesh in hernia repair, abdominal wall defects, reconstruction and treatment of pelvic organ prolapse: a review of the clinical evidence. Am Surgeon 2010;76:1290-9.
7. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010;49:151-7.
8. Rafailidis PI, Bliziotis IA, Falagas ME. Case-control studies reporting on risk factors for emergence of antimicrobial resistance: bias associated with the selection of the control group. Microb Drug Res 2010;16:303-8.
9. Falagas ME, Bliziotis IA, Kosmidis J, Daikos GK. Unusual climatic conditions and infectious diseases: observations made by Hippocrates. Enferm Infecc Microb Clin 2010;28:716-8.
10. Falagas ME, Rafailidis PI, Metthaiou DK. Resistance to polymyxins: mechanisms, frequency

and treatment options. Drug Res Updates 2010;13:132-8.

1. Falagas ME, Vouloumanou EK, Sgouros C, Athanasiou S, Peppas G,Siempos II. Patients included in randomized controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. Int J Antimicrob Agents 2010;36:1-13.
2. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34:506-15.
3. Falagas ME, Michalopoulos A, Metaxas EI. Pulmonary drug delivery systems for antimicrobial agents: facts and myths. Int J Antimicrob Agents 2010;35:101-6.
4. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect. 2009;15:325-34.
5. Pappas G, Saplaoura K, Falagas ME. Current treatment of pseudomonal infections in the elderly. Drugs Aging 2009;26:363-79.
6. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metabolism 2009;10:13-21.
7. Falagas ME, Alexiou VG, Peppas G, Makris GC. Do changes in antimicrobial resistance necessitate reconsideration of surgical antimicrobial prophylaxis strategies? Surg Infect (Larchmt) . 2009;10:557-62.
8. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metabolism 2009;10:2-12.
9. Grammatikos AP, Falagas ME. Linezolid for the treatment of skin and soft tissue infections. Exp Rev Dermatol 2008;3: 539–48.
10. Falagas ME. Interstitial cystitis: an enigmatic disorder of unclear etiology. Nephrol Dial Transplant PLUS 2008;2 80-84.
11. Karageorgopoulos DK, Falagas ME. Current control and treatment of multidrug resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8:751-62.
12. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents . 2009;33:201-5.
13. Vergidis PI, Falagas ME. New antibiotic agents for bloodstream infections. Int J Antimicrob Agents 2008;32:S60-5.
14. Falagas ME, Rafailidis PI. Re-emergence of colistin in the multidrug resistant organism world of today: personal perspectives. Expert Opin Invest Drugs 2008;17:973-81.
15. Vardakas KZ, Falagas ME. Benefit-risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Safety 2008;31:753-68.
16. Iavazzo C, Trompoukis C, Sardi T, Falagas ME. Conception, complicated pregnancy, and labour of gods and heroes in Greek mythology. Reproduct Biomed Online 2008;17:11-4.
17. Falagas ME, Alexiou VG. Top-ten in journal impact factor manipulation. Arch Immunol Ther Exp 2008;56:223-6.
18. Korbila IP, Falagas ME. Investigational antimicrobial drugs for bloodstream infections. Curr Opin Invest Drugs 2008;9:871-8.
19. Pappas G, Fragoulis KN, Falagas ME. World Wide Web resources on zoonotic infections: a subjective overview. Trans Royal Soc Trop Med Hyg 2008;102:1181-8.
20. Vergidis PI, Falagas ME. Multidrug resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Invest Drugs 2008;9:176-83.
21. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Exp Opin Pharmacother 2007;8:2381-400.
22. Rafailidis PI, Ioannidou E, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs 2007;67:1829-49.
23. Falagas ME, Kopterides P. Old antibiotics for the treatment of infections in critically ill patients. Curr Opin Crit Care 2007;13:592-597.
24. Papadavid E, Stratigos AJ, Falagas ME. Imiquimod: An immune response modifier in the treatment of precancerous skin lesions and skin cancer. Exp Opin Pharmacother 2007;8:1743-55.
25. Rafailidis PI, Falagas ME. Fever and periorbital edema: a review. Surv Ophthalmol 2007;52:422-33.
26. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis: a review. Clin Microbiol Infect 2007;13:657-64.
27. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007;102:1510-7.
28. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;29:374-9.
29. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46.
30. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006;58:266-72.
31. Tsiodras S, Falagas ME. Clinical assessment and medical management of spine infections. Clin Orthop Relat Res  2006;444:38-50.
32. Falagas ME, Vergidis PI. Urinary tract infections in patients with urinary diversion. Am J Kidney Dis 2005;46:1030-7.
33. Michalopoulos A, Rizos M, Falagas ME. Severe community-acquired pneumonia (CAP) due to atypical pathogens.Current Respiratory Medicine Reviews 2005;1:265-71.
34. Falagas ME, Vergidis PI. Irrigation with antibiotic-containing solutions for the prevention and treatment of infections. Clin Microbiol Infect 2005;11:862-7.
35. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
36. Falagas ME, Kasiakou SK. Mesh-related infections after hernia repair surgery. Clin Microbiol Infect 2005;11:3-8.
37. Falagas ME, Vergidis PI. Diseases that masquerade as infectious cellulitis.  Ann Intern Med 2005;142:47-55.
38. Falagas ME, Siakavellas E. Bacteroides, Prevotella and Porphyromonas species: a review of antibiotic resistance and therapeutic options. Int J Antimicrob  Agents 2000;15:1-9.
39. Falagas ME, Gorbach SL. Mucopurulent cervicitis and pelvic inflammatory disease. IDCP guidelines.  Infectious Diseases in Clinical Practice 1996;5:6-11.
40. Falagas ME, Gorbach SL. Lyme disease: IDCP guidelines. Infectious Diseases in Clinical Practice 1996;5:210-26.
41. Falagas ME, Gorbach SL. Human papilloma virus, sexually transmitted intestinal infections, ectoparasitic infections, and sexual assault.  IDCP guidelines. Infectious Diseases in Clinical Practice 1996;5:85-93.
42. Falagas ME, Gorbach SL. Genital ulcers. IDCP guidelines. Infectious Diseases in Clinical Practice 1995;4:407-18.
43. Falagas ME, Gorbach SL. Clindamycin and metronidazole. Medical Clinics of North America   1995;79:845-67.
44. Falagas ME, Gorbach SL. Urinary tract infections: Practice guidelines. Infectious Diseases in Clinical Practice 1995;4:241-57.
45. Falagas ME, Snydman DR. Recurrent cytomegalovirus disease in solid-organ transplant recipients. Transplant Proc 1995;27(Suppl 1):34-37.
46. Falagas ME, Gorbach SL. Prostatitis, epididymitis, and urethritis: Practice guidelines.  Infectious Diseases in Clinical Practice 1995;4:325-33.

PUBLICATIONS: CASE REPORT - LITERATURE REVIEWS (PEER-REVIEWED)

1. Peppas G, Makris MC, Falagas ME. Biological mesh for abdominal wall hernia synthetic mesh

MDR P. aeruginosa infection: report of a case. Surg Today 2011;41:717-20.

1. Falagas ME, Rafailidis PI, Kapaskelis A, Peppas G. Pyomyositis associated with hematological malignancy: case report and review of the literature. Int J Infect Dis 2008;12:120-5.
2. Rafailidis PI, Kapaskelis A, Falagas ME. Knee septic arthritis due to Streptococcus pyogenes associated with acute thrombosis of the tibial and peroneal veins: case report and review of the literature. Scand J Infect Dis 2007;39:368-70.
3. Panos GZ, Karydis I, Velakoulis SE, Falagas ME. Multi-skeletal Pneumocystis jiroveci (carinni) in an HIV seropositive patient. Int J STD AIDS 2007;18:134-7.
4. Korres DS, Papagelopoulos PJ, Zahos KA, Kolia MD, Poulakou GG, Falagas ME. Multifocal spinal and extra-spinal Mycobacterium chelonae osteomyelitis in a renal transplant recipient. Transplant Infect Dis 2007;9:62-5.
5. Panos G, KarveliEA, Nikolatou O, Falagas ME. Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J Hematol2007;82:761-5.
6. FalagasME, Bliziotis IA, Mavrogenis AF, Papagelopoulos PJ. Spondylodiscitis after facet joint steroid injection: a case report and review of the literature. Scand J Infect Dis 2006;38:295-9.
7. Fragoulis KN, Handrinou E, Papadopoulos V, Dardoufas K, Falagas ME. Delayed effusive pericarditis and recurrent pleural effusion after radiation treatment for Hodgkin’s disease responsive to per os doxycycline. Eur J Haematol 2006;76:176-9.
8. Falagas ME, Rosmarakis SE. Recurrent post-sternotomy mediastinitis. J Infect 2006;52:e151-4.
9. Rosmarakis ES,  Kapaskelis AM,Rafailidis PI, Falagas ME. Association between Wegener’s granulomatosis and increased antithyroid antibodies: Report of two cases and review of the literature. Int J Clin Pract 2005;59:373-5.
10. Rafailidis PI, Prapas SN, Kasiakou SK, Costeas XF, Falagas ME. Effusive-constrictive calcific pericarditis associated with Streptococcus salivarious: case report and review of the literature. Cardiol Rev 2005;13:113-7.
11. Kasiakou SK, Rafailidis PI, Rosmarakis ES,Falagas ME. Recurrent omphalitis in adults. Scand J Gastroenterol 2004;39:1021-4.
12. Falagas ME, Christopoulou M, RosmarakisES, VlastouC. Munchausen’s syndrome presenting as severe panniculitis. Int J Clin Pract 2004;58:720-2.
13. Papadopoulos E., Papagelopoulos PJ, Savvidou OD, Falagas ME, Sapkas GS, Fragkiadakis EG. Tuberculous sacroilitis. Orthopedics 2003;26:653-7 and 658-9.
14. Papagelopoulos PJ, Sapkas GS, Kateros KT, Papadakis SA, Vlamis JA, Falagas ME. Halo pin intracranial penetration and epidural abscess in a patient with a previous cranioplasty. Case report and review of the literature. Spine 2001;26:E463-E467.
15. Falagas ME, Klempner MS. Babesiosis in patients with AIDS: A chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996;22:809-12.
16. Falagas ME, Griffiths J, Perkezes J, Worthington M.  Cytomegalovirus colitis mimicking colonic carcinoma in an HIV-negative patient with chronic renal failure. Am  J Gastroenterol 1996;91:168-9.

PUBLICATIONS: CONSENSUS PAPER (PEER-REVIEWED)

1. Magiorakos A, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling JM, Struelens MJ, Vatopoulos A,  Weber TJ, Monne DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions. Clin Microbiol Infect (in press).
2. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, Memish ZA, Roushan M, Rubinstein E, Sipsas N, Solera J, Young EJ, Pappas G. Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations. PLoS Med 2007 2007;4:e317.

PUBLICATIONS: ESSAYS (PEER-REVIEWED)

1. Falagas ME, Zarkadoulia EA, Bliziotis IA, Samonis G. Science in ancient and modern Greece: the age of Hippocrates and the age of the genome. FASEB J 2006;20:1946-50.
2. Falagas ME, Kavvadia P. Eigenlob: author self-citation in leading journals. FASEB J 2006;20:1039-42.
3. FalagasME, Zarkadoulia E, Samonis G. Arab science during the golden age and today. FASEB J 2006;20:1581-6.

PUBLICATIONS: PERSPECTIVES (PEER-REVIEWED)

1. Michalopoulos A, Metaxas EI, Falagas ME. Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives. Curr Drug Deliv 2011;8:208-12.
2. Makris GC, Geroulakos G, Makris MC, Mikhailidis DP, Falagas ME. The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. Exp Opin Investig Drugs 2010;19:809-14.
3. Falagas ME, Grammatikos AP, Michalopoulos A. The potential of old generation antibiotics to partially address the current need for new antibiotics. Exp Rev Anti-Infect Ther (in press).
4. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Exp Rev Anti-Infect Ther 2008;6:447-52.

PUBLICATIONS: HYPOTHESES (PEER-REVIEWED)

1. Falagas ME, Makris G. Environmental “probiotics” for nosocomial infection control: a hypothesis. J Hosp Infect 2009;71:301-6.